Overview
The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).
Eligibility
Inclusion Criteria:
- Female sex, age 18-79 years.
- Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
- Baseline LVEF ≥ 55 % by 2-D echocardiography.
- Ability to provide informed consent.
Exclusion Criteria:
- Prior HF, myocardial infarction, or cardiomyopathy.
- Atrial fibrillation or significant valvular heart disease.
- Cumulative anthracycline dose ≥ 250 mg/m².
- Pregnancy or lactation.
- Inability to comply with study procedures.


